According to the industry on the 6th, Chong Kun Dang's Q3 separate basis sales increased 4.6% year-over-year to KRW 427.4 billion. However, operating profit during this period decreased 18.7% to KRW 20.5 billion.
The company explained, "Sales increased as existing products such as Godex, Telmitrend, and Imotun, along with new products including Nurapec and Stivarga, grew evenly," adding, "Operating profit decreased due to increased research and development investment."
Chong Kun Dang's cumulative sales for Q3 this year were KRW 1.256 trillion and operating profit was KRW 55.5 billion. Compared to the same period last year, sales increased 9.5% but operating profit decreased 30.9%. Additionally, the company's R&D expenses increased 23.2% year-over-year to KRW 83.1 billion as of the first half of this year.
Green Cross saw its Q3 consolidated sales increase 31.1% year-over-year to KRW 609.5 billion. This is the first time the company has recorded sales exceeding KRW 600 billion on a quarterly basis. The company analyzed that Alyglo growth and expanded prescription drug sales were key to achieving record quarterly sales.
However, operating profit during the same period fell 26.3% to KRW 29.2 billion. The company explained this was due to external environment changes for some high-margin products. Influenza vaccines switched to trivalent vaccines starting this year, and Hunterase showed a slight decrease due to concentrated overseas supply in the first half.
Despite deteriorating profitability, Hunterase's cumulative Q3 sales reached 96% of last year's annual sales. Accordingly, it is projected to achieve double-digit growth on an annual basis.
Korea United Pharm also recorded sales of KRW 74.3 billion in Q3 this year, up 4.3% year-over-year. However, operating profit decreased 16.9% year-over-year to KRW 12.5 billion. A Korea United Pharm official mentioned, "Drug price cuts and demand slowdown due to economic recession affected profitability."
Some companies saw declines in both sales and operating profit. Yuhan Corporation's Q3 sales decreased 5.8% year-over-year to KRW 551.1 billion, and operating profit fell 55.7% to KRW 24.1 billion. Yuhan Corporation cited decreased royalty income from non-small cell lung cancer treatment Lazertinib (Leclaza) as the reason for poor performance.
The company transferred Lazertinib (Leclaza)'s global commercialization rights to Janssen for KRW 1.4 trillion in 2018. Janssen developed a combination therapy using Lazertinib (Leclaza) with its own anticancer drug Rybrevant, receiving approval from the U.S. Food and Drug Administration (FDA) in August last year.
Yuhan Corporation received KRW 80 billion in Lazertinib (Leclaza) technology royalties in Q3 last year and KRW 20.7 billion in Q2 this year. However, there was no royalty inflow in Q3 this year.
While royalty income decreased, overseas business sales increased 92.7% year-over-year to KRW 135.0 billion. The company is currently strengthening its overseas business revenue structure by continuing its active pharmaceutical ingredient (API) supply contract for human immunodeficiency virus (HIV) treatments with global big pharma Gilead.
A Yuhan Corporation official stated, "We expect Q4 performance to be driven by R&D achievements including receipt of $45 million from Lazertinib (Leclaza)'s commercialization in China, and high growth in the overseas business division."
Yang Hyunwoo (yhw@fntimes.com)



















![12개월 최고 연 4.20%…HB저축은행 'e-회전정기예금'[이주의 저축은행 예금금리-11월 4주]](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=69&h=45&m=5&simg=202611221059260302707c96e797801121481643.jpg&nmt=18)
![24개월 최고 연 4.00%…제주은행 'J정기예금(만기지급식)' [이주의 은행 예금금리-11월 4주]](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=69&h=45&m=5&simg=202611201608410797405e6e69892f5910240225.jpg&nmt=18)
![12개월 최고 연 7.00%…경남은행 '오면우대! 하면우대! 정기적금' [이주의 은행 적금금리-11월 4주]](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=69&h=45&m=5&simg=202611201643200313605e6e69892f5910240225.jpg&nmt=18)
![12개월 최고 연 4.15%…SC제일은행 'e-그린세이브예금' [이주의 은행 예금금리-11월 4주]](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=69&h=45&m=5&simg=202611201607050074605e6e69892f5910240225.jpg&nmt=18)
![24개월 최고 연 7.00%…케이뱅크 '마이키즈 적금' [이주의 은행 적금금리-11월 4주]](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=69&h=45&m=5&simg=202611201645290663905e6e69892f5910240225.jpg&nmt=18)
![[카드뉴스] 서울에서 떠나는 6000년 시간여행, 강동선사문화축제](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=298&h=298&m=1&simg=202611201747364089c1c16452b012411124362_0.jpg&nmt=18)
![[카드뉴스] 강감찬을 만나는 가을, 낙성대로!](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=298&h=298&m=1&simg=202611201536382202c1c16452b012411124362_0.jpg&nmt=18)
![[카드뉴스] 새우젓 따라 만나는 옛 마포나루](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=298&h=298&m=1&simg=20261120114642568c1c16452b012411124362_0.jpg&nmt=18)
![[카드뉴스] 성북동 언덕길, 만해의 집을 만나다](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=298&h=298&m=1&simg=202611171825543540c1c16452b012411124362_0.jpg&nmt=18)
![[카드뉴스] 약재 향 따라 걷는 서울약령시](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=298&h=298&m=1&simg=20261117155133075220c1c16452b012411124362.jpg&nmt=18)
![[AD] 기아, 獨 어워즈서 '비유럽 최초 3관왕'…제네시스 GV60 마그마도 수상](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=89&h=45&m=1&simg=202611110944570572307492587736124111243152.jpg&nmt=18)


![[머니무브 2026] “지금 사도 될까?” 답이 안 보인다면…하반기 투자, 4명의 전문가에게 물어보세요](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=89&h=45&m=1&simg=202609151044050355302a735e27af12411124362.jpg&nmt=18)
![[AD] ‘PBV 라인업 확장’ 기아, 9월 독일서 ‘PV7’ 첫 공개](https://cfnimage.commutil.kr/phpwas/restmb_setimgmake.php?pp=006&w=89&h=45&m=1&simg=2026083111010602815074925877361231180222.jpg&nmt=18)



